DE69635966D1 - (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren - Google Patents

(Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren

Info

Publication number
DE69635966D1
DE69635966D1 DE69635966T DE69635966T DE69635966D1 DE 69635966 D1 DE69635966 D1 DE 69635966D1 DE 69635966 T DE69635966 T DE 69635966T DE 69635966 T DE69635966 T DE 69635966T DE 69635966 D1 DE69635966 D1 DE 69635966D1
Authority
DE
Germany
Prior art keywords
imidazol
methyl
protein transferase
transferase inhibitors
farnesyl protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635966T
Other languages
English (en)
Other versions
DE69635966T2 (de
Inventor
Marc G Venet
Patrick R Angibaud
Philippe Muller
Gerard C Sanz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE69635966D1 publication Critical patent/DE69635966D1/de
Publication of DE69635966T2 publication Critical patent/DE69635966T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69635966T 1995-12-08 1996-10-16 (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren Expired - Lifetime DE69635966T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203427 1995-12-08
EP95203427 1995-12-08

Publications (2)

Publication Number Publication Date
DE69635966D1 true DE69635966D1 (de) 2006-05-18
DE69635966T2 DE69635966T2 (de) 2006-11-30

Family

ID=8220926

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69620445T Expired - Lifetime DE69620445T2 (de) 1995-12-08 1996-10-16 (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
DE69635966T Expired - Lifetime DE69635966T2 (de) 1995-12-08 1996-10-16 (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69620445T Expired - Lifetime DE69620445T2 (de) 1995-12-08 1996-10-16 (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren

Country Status (36)

Country Link
US (3) US6037350A (de)
EP (2) EP0865440B1 (de)
JP (1) JP3257559B2 (de)
KR (1) KR100272676B1 (de)
CN (1) CN1101392C (de)
AP (1) AP1108A (de)
AR (1) AR004992A1 (de)
AT (2) ATE321757T1 (de)
AU (1) AU711142B2 (de)
BG (1) BG62615B1 (de)
BR (1) BR9610745A (de)
CA (1) CA2231105C (de)
CY (1) CY2289B1 (de)
CZ (1) CZ293296B6 (de)
DE (2) DE69620445T2 (de)
DK (2) DK0865440T3 (de)
EA (1) EA000710B1 (de)
EE (1) EE03484B1 (de)
ES (2) ES2260156T3 (de)
HK (2) HK1012188A1 (de)
HR (1) HRP960576B1 (de)
HU (1) HU221227B1 (de)
IL (1) IL123568A (de)
MX (1) MX9802068A (de)
MY (1) MY114444A (de)
NO (1) NO314036B1 (de)
NZ (1) NZ320244A (de)
PL (1) PL184171B1 (de)
PT (2) PT865440E (de)
SI (2) SI1162201T1 (de)
SK (1) SK283335B6 (de)
TR (1) TR199800825T2 (de)
TW (1) TW494101B (de)
UA (1) UA57717C2 (de)
WO (1) WO1997021701A1 (de)
ZA (1) ZA9610254B (de)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
RU2209066C2 (ru) * 1997-06-02 2003-07-27 Янссен Фармацевтика Н.В. Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
US6420555B1 (en) * 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
EP1097150B1 (de) * 1998-06-16 2004-03-24 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazol-derivate
HU229358B1 (en) 1998-07-06 2013-11-28 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ES2199579T3 (es) * 1998-07-06 2004-02-16 Janssen Pharmaceutica N.V. Inhibidores de la proteina farnesil-transferasa con propiedades de sensibilizacion in vivo.
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
WO2000012498A1 (en) 1998-08-27 2000-03-09 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
NZ509372A (en) 1998-08-27 2003-08-29 Pfizer Prod Inc Substituted quinolin-2-one derivatives, pharmaceuticals thereof and their use for treating abnormal cell growth (e.g. cancer)
WO2000034437A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6316436B1 (en) 1998-12-08 2001-11-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69907964T2 (de) * 1998-12-23 2004-02-19 Janssen Pharmaceutica N.V. 1,2-annelierte chinolinderivate
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
OA11833A (en) 1999-02-11 2005-08-23 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents.
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (de) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazol-Derivate
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
ATE284224T1 (de) * 1999-11-09 2004-12-15 Sod Conseils Rech Applic Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g- proteinen in kombination mit einem anderen anti- krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung
ES2212971T3 (es) * 1999-11-30 2004-08-16 Pfizer Products Inc. Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
PT1255537E (pt) * 2000-02-04 2006-09-29 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase para tratar cancro da mama
DE60130976T2 (de) 2000-02-24 2008-07-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2001064198A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
US20030022918A1 (en) * 2000-02-29 2003-01-30 Horak Ivan David Farnesyl protein transferase inhibitor combinations with an her2 antibody
EP1261341A2 (de) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Kombination von farnesyl proteintransferase inhibitoren mit camptothecin-derivaten
JP2003525236A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ビンカアルカロイドとのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
EP1265611A2 (de) * 2000-02-29 2002-12-18 Janssen Pharmaceutica N.V. Kombinationen von farnesyl-protein-transferase-inhibitoren mit taxanen
CA2397253A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US20030125326A1 (en) * 2000-02-29 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations
US20030212008A1 (en) * 2000-02-29 2003-11-13 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AU2001235496A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
EP1261356A2 (de) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Kombination von farnesyl proteintransferase inhibitoren mit einer platin-koordinationsverbindung
AU2001256166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
AU2002220559A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
EP1322635B1 (de) 2000-09-25 2006-03-22 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
WO2002024683A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
US7067531B2 (en) * 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
ATE434615T1 (de) 2000-11-21 2009-07-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
US20040044032A1 (en) * 2000-11-28 2004-03-04 End David William Farnesyl protein transfer inhibitors for the treatment of inflammatory bowel disease
AU2002218436A1 (en) 2000-12-19 2002-07-01 Pfizer Products Inc. Crystal forms of 6-((4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl) -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production
DE60119383T2 (de) * 2000-12-27 2007-04-19 Janssen Pharmaceutica N.V. Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
WO2002051835A1 (en) * 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
MXPA03008205A (es) * 2001-03-12 2004-01-29 Janssen Pharmaceutica Nv Procedimiento para la preparacion de compuestos de imidazol.
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
EP1412367A4 (de) * 2001-06-21 2006-05-03 Ariad Pharma Inc Neue chinoline und deren verwendung
US6713462B2 (en) 2001-06-21 2004-03-30 Ariad Pharmaceuticals, Inc. Quinolinones and uses thereof
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US20030134846A1 (en) * 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
WO2003051880A1 (en) 2001-12-19 2003-06-26 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ATE364384T1 (de) 2002-03-22 2007-07-15 Janssen Pharmaceutica Nv Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2497628A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
BRPI0412876A (pt) * 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US7825131B2 (en) 2003-09-23 2010-11-02 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
EP1744751A4 (de) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
CA2559282A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CN100567292C (zh) 2004-05-03 2009-12-09 詹森药业有限公司 制备咪唑化合物的非对映选择性合成方法
EP1756085B1 (de) 2004-05-03 2010-06-16 Janssen Pharmaceutica N.V. Diastereoselektives syntheseverfahren mit 6-brom-4-(3-chlorphenyl)-2-methoxychinolin
EP1758885B1 (de) 2004-05-03 2008-06-18 Janssen Pharmaceutica N.V. Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP2422811A2 (de) 2004-10-27 2012-02-29 MedImmune, LLC Modulation von Antikörperspezifität mittels Anpassung der Affinität zu verwandten Antigenen
PL2362218T3 (pl) * 2004-11-05 2015-02-27 Janssen Pharmaceutica Nv Sposoby kontroli skuteczności inhibitorów transferazy farnezylowej
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1869192B1 (de) 2005-03-18 2016-01-20 MedImmune, LLC Rahmenmischung von antikörpern
EP1888050B1 (de) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
EP1893647A2 (de) 2005-06-23 2008-03-05 MedImmune, Inc. Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
EP1945182B1 (de) * 2005-10-14 2010-07-28 Janssen Pharmaceutica N.V. Formulierungen von tipifarnib zur intravenösen verabreichung
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
WO2007124316A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
RU2475483C2 (ru) 2006-04-20 2013-02-20 Янссен Фармацевтика Н.В. Ингибиторы с-fms киназы
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
MX2009007200A (es) 2007-01-10 2009-07-15 Angeletti P Ist Richerche Bio Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
EP2132177B1 (de) 2007-03-01 2013-07-17 Novartis AG Pim-kinase-hemmer und verfahren zu ihrer verwendung
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
RU2491094C2 (ru) 2007-03-30 2013-08-27 Медиммун, Ллк Препарат антитела
JO2959B1 (en) 2007-05-14 2016-03-15 جانسين فارماسوتيكا ان. في Mono-hydrochloric salts for histone dacetylase inhibitor
EP2152700B1 (de) 2007-05-21 2013-12-11 Novartis AG Csf-1r-hemmer, zusammensetzungen und anwendungsverfahren
JP2010528034A (ja) * 2007-05-23 2010-08-19 アラーガン、インコーポレイテッド 医薬としての（（フェニル）イミダゾリル）メチルキノリニル化合物
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
EP2200985B1 (de) 2007-09-14 2011-07-13 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin-2-one
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
AU2008319298B2 (en) 2007-10-31 2014-07-31 Medimmune, Llc Protein scaffolds
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CA2710122A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
WO2010056985A2 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
BRPI0920927A2 (pt) * 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
MX2011011962A (es) 2009-05-12 2012-02-28 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
ME01573B (me) 2009-05-12 2014-09-20 Addex Pharma Sa DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EA023838B1 (ru) 2009-10-14 2016-07-29 Мерк Шарп Энд Домэ Корп. ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CA2791613A1 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
CA3186328A1 (en) 2010-07-28 2012-02-02 Janssen Pharmaceutica Nv Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328195B2 (en) 2010-11-08 2015-04-02 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
EP2668210B1 (de) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit-antikörper und ihre verwendungen
ES2611885T3 (es) 2011-01-31 2017-05-11 Novartis Ag Derivados heterocíclicos novedosos
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
PL2771342T3 (pl) 2011-10-28 2016-11-30 Nowe pochodne puryny i ich zastosowanie w leczeniu chorób
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
EP3453762B1 (de) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Sina-zusammensetzungen
SG10201608469RA (en) 2012-05-16 2016-11-29 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
AU2013295848B2 (en) 2012-07-25 2018-05-24 Celldex Therapeutics, Inc. Anti-KIT antibodies and uses thereof
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
IN2015DN00659A (de) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
US20150231240A1 (en) 2012-10-09 2015-08-20 Igenica Biotherapeutics, Inc. Anti-c16orf54 antibodies and methods of use thereof
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
MX358508B (es) 2012-10-16 2018-08-22 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t.
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
ME02925B (de) 2012-11-28 2018-04-20 Merck Sharp & Dohme Zusammensetzungen und verfahren zur behandlung von krebs
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (de) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
RS62189B1 (sr) 2013-08-26 2021-08-31 Biontech Research And Development Inc Nukleinske kiseline koje kodiraju humana antitela na sijalil-luis a
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
EP3057421B1 (de) 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkylgebundene chinolinylmodulatoren von roryt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
CN105979947A (zh) 2013-12-06 2016-09-28 诺华股份有限公司 α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CA2950602C (en) 2014-06-04 2021-07-20 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CN114230664A (zh) 2014-12-11 2022-03-25 皮埃尔法布雷医药公司 抗c10orf54抗体及其用途
EP3236959A4 (de) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
DE112016001013T5 (de) 2015-03-03 2017-12-21 Kymab Limited Antikörper, verwendungen und verfahren
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
SG10202101740QA (en) * 2015-08-17 2021-04-29 Kura Oncology Inc Methods of treating cancer patients with farnesyl transferase inhibitors
WO2017034877A1 (en) * 2015-08-27 2017-03-02 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3370719A1 (de) 2015-11-02 2018-09-12 Novartis AG Dosierungsplan für einen phosphatidylinositol-3-kinase-inhibitor
CN109415437B (zh) 2015-12-02 2022-02-01 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
US10954210B2 (en) 2016-12-08 2021-03-23 Hangzhou Solipharma Co., Ltd. Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof
EP3609922A2 (de) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp-alpha-antikörper
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
AU2018277545A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
CN111630069B (zh) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
KR20210039987A (ko) 2018-05-18 2021-04-12 쿠라 온콜로지, 인크. 티피파닙의 합성
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
AU2022399572A1 (en) 2021-11-30 2024-05-02 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
WO2023141082A1 (en) * 2022-01-20 2023-07-27 Teva Czech Industries S.R.O. Solid state forms of tipifarnib and process for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101115A (en) * 1980-10-23 1983-01-12 Pfizer Ltd Thromboxane synthetase inhibitors
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren

Also Published As

Publication number Publication date
EP0865440B1 (de) 2002-04-03
JPH10511405A (ja) 1998-11-04
NO980927L (no) 1998-06-08
CZ293296B6 (cs) 2004-03-17
US6169096B1 (en) 2001-01-02
HUP9900185A2 (hu) 1999-04-28
CA2231105C (en) 2005-09-13
TR199800825T2 (xx) 1998-08-21
EE9800146A (et) 1998-10-15
HK1042482A1 (en) 2002-08-16
HK1012188A1 (en) 1999-07-30
DE69620445T2 (de) 2002-12-12
TW494101B (en) 2002-07-11
PL325962A1 (en) 1998-08-17
HRP960576B1 (en) 2002-04-30
BG102458A (en) 1999-06-30
PT1162201E (pt) 2006-08-31
ZA9610254B (en) 1998-06-05
UA57717C2 (uk) 2003-07-15
AR004992A1 (es) 1999-04-07
ES2175137T3 (es) 2002-11-16
DK0865440T3 (da) 2002-07-22
ATE215541T1 (de) 2002-04-15
NO314036B1 (no) 2003-01-20
SK70498A3 (en) 1998-10-07
SI1162201T1 (sl) 2006-08-31
AP1108A (en) 2002-10-02
PL184171B1 (pl) 2002-09-30
HK1042482B (zh) 2006-06-09
EP0865440A1 (de) 1998-09-23
NZ320244A (en) 1999-06-29
DE69635966T2 (de) 2006-11-30
SK283335B6 (sk) 2003-06-03
DK1162201T3 (da) 2006-07-17
HU221227B1 (en) 2002-08-28
AP9801257A0 (en) 1998-06-30
HUP9900185A3 (en) 1999-11-29
EP1162201B1 (de) 2006-03-29
US6037350A (en) 2000-03-14
IL123568A0 (en) 1998-10-30
EA000710B1 (ru) 2000-02-28
SI0865440T1 (en) 2002-08-31
CY2289B1 (en) 2003-07-04
AU7294896A (en) 1997-07-03
IL123568A (en) 2001-08-08
HRP960576A2 (en) 1998-02-28
CA2231105A1 (en) 1997-06-19
BG62615B1 (en) 2000-03-31
EP1162201A3 (de) 2003-11-26
AU711142B2 (en) 1999-10-07
JP3257559B2 (ja) 2002-02-18
CN1203598A (zh) 1998-12-30
KR19990063891A (ko) 1999-07-26
EA199800443A1 (ru) 1998-10-29
US6420387B1 (en) 2002-07-16
CZ157398A3 (cs) 1998-10-14
MX9802068A (es) 1998-08-30
PT865440E (pt) 2002-09-30
WO1997021701A1 (en) 1997-06-19
NO980927D0 (no) 1998-03-04
MY114444A (en) 2002-10-31
CN1101392C (zh) 2003-02-12
EP1162201A9 (de) 2002-04-03
EP1162201A2 (de) 2001-12-12
DE69620445D1 (de) 2002-05-08
EE03484B1 (et) 2001-08-15
ES2260156T3 (es) 2006-11-01
BR9610745A (pt) 1999-07-13
ATE321757T1 (de) 2006-04-15
KR100272676B1 (ko) 2000-11-15

Similar Documents

Publication Publication Date Title
ATE215541T1 (de) (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
NO974457D0 (no) Inhibitorer for farnesylproteintransferase
ATE185341T1 (de) 4,9-ethano-benzo(f)isoindolderivate als farnesyl transferase inhibitoren
NO996571L (no) Inhibitorer for farnesyl-protein-transferase
NO983892L (no) Inhibitorer for farnesyl-proteintransferase
EE9800408A (et) Proteiinfarnesüültransferaasi inhibiitorid
NO20024950D0 (no) 4-Merkaptopyrrolidinderivater som farnesyltransferaseinhibitorer
NO951647D0 (no) Inhibitorer for farnesylproteintransferase
FI951554A0 (fi) Imidatsolipitoisia farnesyyliproteiinitransferaasi-inhibiittoreita
DK1019395T3 (da) Farnesyltransferasehæmmende 2-quinolonderivater
DE69627179T2 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
ATE172199T1 (de) Proteinkinase-c-inhibitor
ATE293622T1 (de) Farnesyl protein transferase inhibitoren
ATE273307T1 (de) Benzo(5,6)cycloheptapyridin derivate anwendbar als farnesyl protein transferase inhibitoren
FI953170A0 (fi) Oligunokleotidit isoprenyyliproteiinitransferaasin ilmentämisen inhibiboimiseksi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition